Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04904120 · ClinicalTrials.gov registry record · Phase 1
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
A Phase 1 study, sponsored by Perspective Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT04904120 is a Phase 1 study that has completed, run by Perspective Therapeutics. The registered enrollment target is 7 participants.
The verdict
NCT04904120, a Phase 1 study, has completed, sponsored by Perspective Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The study hypothesis is that new imaging agents \[203Pb\]VMT01 and \[68Ga\]VMT02 can be safely used in humans without independent biological effect and can be used to image melanoma tumors expressing the melanocortin sub-type 1 receptor (MC1R) by SPECT/CT and PET/CT imaging modalities respectively.
Interventions
- DRUG [203Pb]VMT01
- DRUG [68Ga]VMT02
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-03-05 |
| Est. Completion | 2022-09-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04904120
The ClinicalTrials.gov registry entry for NCT04904120 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Perspective Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which [203Pb]VMT01 is the first listed.
NCT04904120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04904120 about?
NCT04904120 is a clinical study titled "Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy". The study hypothesis is that new imaging agents \[203Pb\]VMT01 and \[68Ga\]VMT02 can be safely used in humans without independent biological effect and can be used to image melanoma tumors expressing the melanocortin sub-type 1 receptor (MC1R) by SPECT/CT and PET/CT imaging modalities respectively.
What is the current status of trial NCT04904120?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2021-03-05. Estimated completion is 2022-09-20.
What interventions are being tested in trial NCT04904120?
The interventions under investigation include: [203Pb]VMT01 (DRUG), [68Ga]VMT02 (DRUG).
Who is sponsoring clinical trial NCT04904120?
This trial is sponsored by Perspective Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.